Brief: Galapagos Announces Start Of Phase 2 Study With Selective TYK2 Inhibitor, GLPG3667
23/05/2023 22:25
May 23 (Reuters) - Galapagos NV GLPG.AS :
* GALAPAGOS ANNOUNCES START OF PHASE 2 STUDY WITH SELECTIVE
TYK2
INHIBITOR, GLPG3667, IN PATIENTS WITH DERMATOMYOSITIS
Source text for Eikon: ID:nGNX4LXM2X
Further company coverage: GLPG.AS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lakefront Biotherapeutics NV
See all newsBrief: Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
Brief: Lakefront Receives Transparency Notification From Bank Of America
Belgium's Galapagos Q1 revenue falls 91% but returns to profit
Brief: Galapagos, Gilead Enter Binding Agreement On Ouro Medicines Acquisition
Brief: Galapagos Announces Nomination Of Gino Santini To Its Board Of Directors